Modified vaccinia virus strains for use in diagnostic and therapeutic methods
AssigneeGenelux Corporation
InventorsAladar A. Szalay, Alexa Frentzen, Yong A. Yu, Nanhai Chen, Qian Zhang
Life of this patent
Estimating the term…
Abstract
Modified viruses and methods for preparing the modified viruses are provided. Vaccines that contain the viruses are provided. The viruses can be used in methods of treatment of diseases, such as proliferative and inflammatory disorders, including cancer, and as anti-tumor and/or antiangiogenic agents. The viruses also can be used in diagnostic methods.
Claims19
A recombinant vaccinia virus that encodes a diagnostic or therapeutic protein, wherein the diagnostic or therapeutic protein is selected from among a ferritin, CBG99-mRFP1, plasminogen kringle 5 domain, a soluble IL-6 receptor-IL-6 fusion protein (sIL-6R/IL-6), interleukin-24 (IL-24), a truncated human tissue factor protein fused to an RGD peptide (tTF-RGD) and an anti-VEGF single chain antibody or fragment thereof, wherein the nucleic acid encoding the diagnostic or therapeutic protein is inserted into a non-essential locus in the virus.
A recombinant replication competent vaccinia virus that encodes a diagnostic or therapeutic protein that comprises a soluble IL-6 receptor-IL-6 fusion protein (sIL-6R/IL-6), an anti-vascular endothelial growth factor (VEGF) single chain antibody or fragment thereof, wherein the nucleic acid encoding the diagnostic or therapeutic protein is inserted into a non-essential locus in the virus and is operatively linked to a promoter for expression.
A recombinant replication competent vaccinia virus that encodes a diagnostic or therapeutic protein that comprises a soluble IL-6 receptor-IL-6 fusion protein (sIL-6R/IL-6) and that comprises an inactivated hemagglutinin (HA) gene, thymidine kinase (TK) gene or F14.5L gene.
Dependencies are inferred from the claim text.